Recurrent Gastric Cancer Completed Phase 2 Trials for Saracatinib (DB11805)

Also known as: Gastric cancer recurrent / Stomach cancer recurrent / Stomach carcinoma recurrent / Gastric carcinoma recurrent

IndicationStatusPhase
DBCOND0028800 (Recurrent Gastric Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00607594Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction CancerTreatment